AstraZeneca and Bristol-Myers Squibb Diabetes Alliance provides $5 million grant for American Diabetes Association's Pathway to Stop Diabetes
- Details
- Category: Bristol-Myers Squibb
AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies' U.S. Diabetes Alliance is providing a three-year grant to the American Diabetes Association's Pathway to Stop Diabetes program. The innovative research initiative provides resources and support for a new generation of diabetes researchers and is designed to generate exciting discoveries through excellence, innovation, collaboration and radical thinking.
Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Tafinlar® (dabrafenib) for treatment of patients with metastatic BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy.
MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
- Details
- Category: AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collaboration and licensing agreement with Immunocore Limited, a privately-held, UK-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.
Bayer and Peking University establish new research center for translational research and drug discovery in Beijing
- Details
- Category: Bayer
Bayer HealthCare and Peking University (PKU), Beijing, China, have signed a comprehensive collaboration agreement on a three-year strategic partnership to promote translational research for drug discovery. Under this agreement, the two partners will establish a joint research center at Peking University under the name Bayer HealthCare/Peking University Center of Translational Research for Drug Discovery (BPC/TRDD).
GSK adds detailed clinical trial data to multi-sponsor request system
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system that includes studies from multiple organisations.
Bayer plans to acquire Norwegian pharmaceutical company Algeta
- Details
- Category: Bayer
The Bayer Group plans to further strengthen its oncology portfolio with the acquisition of Norwegian pharmaceutical company Algeta ASA, Oslo. "We have already successfully collaborated with Algeta to develop and commercialize the cancer drug Xofigo™. The planned acquisition would give us full control over Xofigo™. We are absolutely convinced of the potential of this drug and the underlying technology to provide patients with innovative treatment options," commented Bayer CEO Dr. Marijn Dekkers.
Bristol-Myers Squibb to sell its global diabetes business
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.
More Pharma News ...
- Pfizer settles Viagra® patent litigation with Teva
- Lundbeck and Otsuka to co-develop Lu AF20513, an investigational vaccine against Alzheimer's disease
- FDA Advisory Committee votes on investigational medicine metreleptin
- Multimillion pound investment in UK life sciences research and development
- Pfizer expands clinical trial data access policy and launches data access portal
- Novartis Africa Day highlights company's efforts to expand access to healthcare
- Only 29% of people with diabetes report that their doctors ask them for input for their own treatment plans